Mettler-Toledo International 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Mettler Toledo reported 3rd quarter 2026 sales of $1.1 billion, up 6% in US dollars and local currencies, with organic local currency sales growth also of 6%.
- Organic sales increased 3% in the Americas, 2% in Europe, and 13% in Asia rest of world, including 13% growth in China.
- Organic sales increased 6% in laboratory and 6% in industrial, including 5% growth in core industrial and 8% growth in product inspection; food retail declined 2%, while service revenue grew 7%.
- Gross margin was 59.8%, up 60 basis points; adjusted operating profit was $333.5 million, up 8%, and adjusted operating margin was 30.5%, up 40 basis points.
- Adjusted EPS was $12.57, up 13%; reported EPS was $12.29, compared with $10.57 in the prior year.
- Year-to-date adjusted free cash flow was $652 million and was negatively impacted by tax payments that were $72 million higher than the prior year; excluding taxes, free cash flow per share increased 7%.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I will now hand the conference over to Adam Uhlman, Head of Investor Relations.
Please go ahead. Hey, thanks, Jonathan.
Good morning, everyone. I appreciate you joining us. On the call with me today is Patrick Kaltenbach, our Chief Executive Officer, and Shawn Vadala, our Chief Financial Officer. Let me cover some administrative matters. This call is being webcast and is available for replay on our website at mt.com. A copy of the press release and the presentation that we will refer to on today's call is also available on our website. This call will include forward-looking statements within the meaning of the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934. These statements involve risks, uncertainties, and other factors that may cause our actual results, financial condition, performance, and achievements to be materially different from those expressed or implied by any forward-looking statement.
For a discussion of these risks and uncertainties, please see our recent annual report on Form 10-K and quarterly and recent reports filed with the SEC. The company disclaims any obligation or undertaking to provide updates or revisions to any forward-looking statement, except as required by law. On today's call, we will use non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure is provided in the eight-K and is available on our website. Let me now turn the call over to Patrick.
Thank you, Adam, and good morning, everyone. We appreciate you joining our call today. Last night, we reported our third quarter financial results, the details of which are outlined for you on page three of our presentation. We delivered an excellent third quarter, achieving relatively broad-based growth across our portfolio while capitalizing on improving market demand. Performance was particularly strong in Asia and the rest of the world. Improved sales volume and strong execution of our strategic initiatives resulted in another quarter of robust growth in adjusted EPS. We continue to benefit from investments in recent years that have strengthened our competitive position and prepared us for the growth opportunities we see ahead of us. We have accelerated our innovation, expanded our digital capabilities, further enhanced our Spinnaker sales and marketing excellence program, and evolved our global supply chain setup for increased resilience and agility.
As market conditions improve, we are well-positioned to deliver strong financial performance going forward. Let me now turn the call over to Shawn to cover the financial results and our guidance, and I will come back with some additional commentary on the business and our outlook.
Shawn? Thanks, Patrick, and good morning, everyone.
Sales in the quarter were $1.1 billion, up 6% in U.S. dollars and in local currencies. Organic local currency sales growth was also 6%. On slide number four, we show local currency sales growth by region. Organic sales increased 3% in the Americas, 2% in Europe, and 13% in Asia and rest of world, including 13% growth in China. Slide number five shows sales growth by region on a year-to-date basis. On slide number six, we summarize sales growth by product area. Organic sales increased 6% in Laboratory and 6% in Industrial, which included 5% growth in core Industrial and 8% growth in Product Inspection. Food Retail declined 2% in the quarter. Lastly, service revenue grew 7%. Slide number seven details sales growth by product area on a year-to-date basis.
Let me now move to the rest of the P&L, which is summarized on slide number eight. Gross margin was 59.8% in the quarter, an increase of 60 basis points due to benefits from favorable price realization, lower tariff rates compared to the prior year, and volume growth, partially offset by higher material and transportation costs. R&D amounted to $54 million in the quarter and was up 4% on a local currency basis over the prior period. SG&A amounted to $267 million, an 8% increase in local currency over the prior year, and includes sales and marketing investments and higher variable compensation, offset in part by cost savings. Adjusted operating profit amounted to $333.5 million in the quarter, up 8% versus the prior year. Adjusted operating margin was 30.5%, an increase of 40 basis points versus the prior year.
Adjusted EPS for the quarter was $12.57, a 13% increase over the prior year. On a reported basis in the quarter, EPS was $12.29 as compared to $10.57 in the prior year, and a reconciliation to GAAP is located in our press release. That covers the P&L, and let me now comment on adjusted free cash flow, which amounted to $652 million on a year-to-date basis and was negatively impacted by the timing of tax payments, which were $72 million higher than the prior year. Excluding taxes, free cash flow per share increased 7% versus the prior year. I'll now share additional thoughts on our guidance for the fourth quarter and our initial thoughts for 2027. As you review our guidance, please keep in mind the following factors.
First, we are encouraged by the relatively broad-based momentum in our business, especially in China and emerging markets. Second, conditions in the Middle East remain volatile, and while we have limited exposure to the region, this could impact customer decision-making should conditions significantly change. We are not currently seeing any change in related customer behavior and have not included an escalation of the conflict in our forecast. Third, while we are encouraged by the increasing momentum and activity related to onshoring investments, we have not assumed this will be meaningful to our 2027 results. Lastly, we are very confident in our ability to execute on our growth and productivity initiatives and believe we are well-positioned to gain market share regardless of the macro environment. Now, turning to our guidance.
For the fourth quarter 2026, our local currency sales growth forecast is approximately 5%, and adjusted EPS is forecast to be in the range of $14.84-$15.04, which represents a growth rate of 11%-13%. At recent spot rates, foreign exchange is not expected to significantly impact our results. For the full year 2026, we have increased our local currency sales growth forecast from approximately 4%-5% to approximately 5%, reflecting organic growth of 4%. Note that our forecast also excludes the impact on sales and cost of sales from tariff refunds. Adjusted EPS is forecast to be in the range of $47.70-$47.90, which represents a growth rate of 12%.
We have also provided our initial guidance for 2027, and based on our assessment of market conditions today, we expect local currency sales to increase approximately 5%. Our outlook reflects continued strength in China and emerging markets, favorable trends in the U.S., and benefits from our Spinnaker sales and marketing growth initiatives and robust product portfolio, offset in part by a cautious view in Europe given various macro uncertainties. Adjusted EPS is forecast to be in the range of $52.50-$53.50, which represents a growth rate of 10%-12%. At recent spot rates, foreign exchange is estimated to be a 1% headwind to sales growth and neutral to EPS. Some further comments on our 2027 guidance. We expect total amortization, including purchased intangible amortization, to be approximately $76 million.
Purchased intangible amortization is excluded from adjusted EPS and is estimated at $27 million on a pre-tax basis, or approximately $1.05 per share. Interest expense is forecast at $68 million for the year. Other income is estimated at approximately $22 million. We expect our tax rate before discrete items will decline from 19% in 2026 to 18% in 2027. Free cash flow is expected to be approximately $950 million in 2027, which represents 8% growth on a per-share basis. Share repurchases are also expected to be $950 million. That is it from my side, and I will now turn it back to Patrick.
Thanks, Shawn. Let me start with some comments on our operating businesses, starting with Lab, which had broad-based growth in the quarter across nearly all product areas. In addition to growth in bioprocessing, it was encouraging to see another quarter of strong growth from customers in quality labs, where we sell a wide range of analytical instruments and lab balances, while trends in biopharma and biotech research improved, resulting in very strong growth in our liquid handling business. The portfolio also benefited from growth in hot segments this quarter, like semiconductor, battery, and GLP-1, among others. Our innovative portfolio resonates well with customers, and we have a deep pipeline of new innovations that will reinforce our technology leadership. In process analytics, we launched a new online bioburden analyzer that provides real-time monitoring of microbial contamination, for example, in pharmaceutical water systems.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
